恶性肿瘤患者血清胱抑素C和可溶性尿激酶受体检测的临床意义

目的:探讨恶性肿瘤患者血清胱抑素C(Cystatin C)和可溶性尿激酶受体(suPAR)水平与肿瘤浸润转移和治疗的关系.方法:Cystatin C应用颗粒增强散射免疫比浊法(PENIA)检测;suPAR采用ELISA法检测.共检测了82例健康成人和172例恶性肿瘤患者血清Cystatin C和suPAR水平并进行比较.结果:恶性肿瘤患者血清Cystatin C和suPAR水平较健康对照组显著增高(P＜0.01和P＜0.01),差异有显著性;中晚期、已转移组的肿瘤患者Cystatin C和suPAR测定值均显著高于各自对照组;在治疗过程中,患者血清Cystatin C和suPAR水平,术后与术前比较,两组指标均明显降低,但接受化疗及放疗的患者,血清Cystatin C和suPAR水平与治疗与否无差异.结论:恶性肿瘤患者血清Cystatin C和suPAR水平与肿瘤细胞的浸润转移以及手术治疗有关.检测血清Cystatin C和suPAR水平对恶性肿瘤患者的病情监测和疗效判断有重要的临床价值.

Clinical Value of Serum Cystatin C and suPAR Assay in Patients with Malignant Tumor

Objective To explore the relationship of serum level of Cystatin C and suPAR with tumor infiltration, metastasis, and treatment of patients with malignant tumor. Methods: The serum levels of Cystatin C was detected by particle enhanced nephelometic immunoassay (PENIA) by 7600-010 full-automatic biochemical analyzer made in Japan. The level of suPAR was detected by ELISA. The serum levels of Cystatin C and suPARof 82 normal adults and 172 patients with malignant tumor were measured and compared. Results: The serum level of Cystatin C and suPAR in patients with malignant tumor was significantly increased compared with that of normal adults (P＜0.01 and P＜0.01). The level of Cystatin C and suPAR in terminally ill patients or patients with metastasis was significantly higher than that in the control group. The levels of the two indices in postoperative patients were lower than those in preoperative patients. No significant difference was found in the levels of the two indicies before chemotherapy or radiotherapy and after therapy. Conclusion: The serum levels of Cystatin C and suPARin patients with malignant tumor are correlated with tumor invasion, metastasis and surgical intervention. Detection of Cystatin C and suPAR levels in patients with malignant tumor is valuable for disease monitoring and treatment evaluation.